Latest News-GC Corp. Mediaroom_Page

GC Genome Study Identifies 'Confounders' Interfering with Cancer Signals to Improve Liquid Biopsy Accuracy

YONGIN, South Korea, Dec. 9, 2025 /PRNewswire/ -- GC Genome, a leading clinical genomics and liquid...

2025-12-09 14:54 769

GC Biopharma Ships First Doses of World's First Recombinant Anthrax Vaccine, 'BARYTHRAX inj.'

- First anthrax vaccine developed using recombinant DNA technology - Annual production capacity of u...

2025-12-08 14:36 810

GC Biopharma's Varicella Vaccine Strain 'MAV/06' Listed in WHO Position Paper

* Officially recognized by WHO as a standard varicella vaccine strain alongside Oka * Interchan...

2025-12-02 13:00 907

GC Genome Publishes Blood-Based Colorectal Cancer Screening Study in the American Journal of Gastroenterology

YONGIN, South Korea, Nov. 27, 2025 /PRNewswire/ -- GC Genome, a leading clinical genomics and liqui...

2025-11-27 13:00 890

GC Biopharma's Recombinant Anthrax Vaccine, BARYTHRAX, Demonstrates Safety and Immunogenicity in Phase 2 Data, Published in 'Vaccine'

YONGIN, South Korea, Nov. 3, 2025 /PRNewswire/ -- GC Biopharma, a leading global pharmaceutical com...

2025-11-03 13:26 995

GC Biopharma Secures CMO Rights for Shingles Vaccine from Curevo Vaccine

YONGIN, South Korea, Oct. 13, 2025 /PRNewswire/ -- GC Biopharma (006280.KS), a South Korean biophar...

2025-10-13 12:38 1083

GCCL and Frontage Laboratories Announce Strategic Collaboration to Strengthen Global Clinical Trial Capabilities

YONGIN, South Korea, Sept. 24, 2025 /PRNewswire/ -- GCCL (Global Clinical Central Lab), aSouth Kore...

2025-09-24 13:29 1574

GC Biopharma Submits IND Application for Phase 1 Clinical Trial of COVID-19 mRNA Vaccine in Korea

YONGIN, South Korea, Sept. 22, 2025 /PRNewswire/ -- GC Biopharma (006280.KS), a leading South Korea...

2025-09-23 09:41 1446

GC Biopharma's Study on Hunterase Lysosomal Delivery Mechanism Published in SCIE-Indexed Journal

YONGIN, South Korea, Aug. 21, 2025 /PRNewswire/ -- GC Biopharma, a leading global pharmaceutical co...

2025-08-21 13:00 1408

GC Biopharma Signs MOU with Thai Red Cross Society to Strengthen Collaboration on Plasma-Derived Therapies

YONGIN, South Korea, Aug. 18, 2025 /PRNewswire/ -- GC Biopharma (006280.KS), a South Korean biophar...

2025-08-18 12:40 1487

GC Biopharma Receives Marketing Authorization for BARYCELA in Vietnam

YONGIN, South Korea, July 17, 2025 /PRNewswire/ -- GC Biopharma (006280.KS), a South Korean pharmac...

2025-07-17 13:56 1623

GC Biopharma's Phase 3 Clinical Trial Results for Hunterase Published in SCIE-Indexed Journal

YONGIN, South Korea, May 30, 2025 /PRNewswire/ -- GC Biopharma, a South Korean pharmaceutical compa...

2025-05-30 15:02 2078

GC Biopharma Receives FDA Approval for its U.S. Plasma Collection Center in Calexico, California

YONGIN, South Korea, May 14, 2025 /PRNewswire/ -- GC Biopharma, a South Korean pharmaceutical compa...

2025-05-14 13:21 1924

GC Biopharma Receives MFDS Approval for World's First Recombinant Anthrax Vaccine

YONGIN, South Korea, April 9, 2025 /PRNewswire/ -- GC Biopharma announced 09. Apr. 2025 that the Ko...

2025-04-09 12:00 2319

GC Biopharma Shares Research Updates on Rare Disorder Drugs at the WORLD Symposium 2025

YONGIN, South Korea , Feb. 11, 2025 /PRNewswire/ -- GC Biopharma, a South Korean biopharmaceutical ...

2025-02-11 16:40 1934

GCCL Wins 2025 Asia-Pacific Customer Value Leadership Award by Frost & Sullivan

- GCCL's "One-Stop Lab Solution" sets the industry benchmark with unmatched competitiveness an...

2025-02-07 09:31 2518

GC Biopharma and Novel Pharma First Patient Dosed in Global Phase I Clinical Trial for MPS IIIA Treatment

YONGIN, South Korea, Nov. 25, 2024 /PRNewswire/ -- GC Biopharma and Novel Pharma today announced th...

2024-11-26 08:44 2232

GC Biopharma and Novelty Nobility Enter into Joint Research and Development Agreement for Geographic Atrophy Therapies

YONGIN, South Korea, Oct. 28, 2024 /PRNewswire/ -- GC Biopharma announced that it has signed an agr...

2024-10-29 09:13 2447

GC Biopharma and Hanmi Pharmaceutical Receives IND Clearance for Phase 1/2 Clinical Trial from the U.S. FDA

* Co-development of innovative new drug for the treatment of Fabry disease as "the world's first ...

2024-09-03 15:59 1829

GCCL Completes Proactive Development of Biosimilar Clinical Trial Analysis Methods, Providing Customized Analysis Services through Enhanced R&D Capabilities

* Newly established R&D division this year is expected to provide full-scale in-house R&D in addi...

2024-07-17 10:38 2134